TrialCardiovascular diabetology2023

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.

Martin Benedikt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.